These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21700212)

  • 21. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.
    Reczek D; Schwake M; Schröder J; Hughes H; Blanz J; Jin X; Brondyk W; Van Patten S; Edmunds T; Saftig P
    Cell; 2007 Nov; 131(4):770-83. PubMed ID: 18022370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
    Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW
    J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
    van Weely S; van den Berg M; Barranger JA; Sa Miranda MC; Tager JM; Aerts JM
    J Clin Invest; 1993 Mar; 91(3):1167-75. PubMed ID: 8450045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potent 1,4-dihydropyridine L-type calcium channel blocker, benidipine, promotes osteoblast differentiation.
    Nishiya Y; Kosaka N; Uchii M; Sugimoto S
    Calcif Tissue Int; 2002 Jan; 70(1):30-9. PubMed ID: 11907705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes.
    Cerbai E; Giotti A; Mugelli A
    Br J Pharmacol; 1997 Feb; 120(4):667-75. PubMed ID: 9051306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts.
    Choudary PV; Barranger JA; Tsuji S; Mayor J; LaMarca ME; Cepko CL; Mulligan RC; Ginns EI
    Mol Biol Med; 1986 Jun; 3(3):293-9. PubMed ID: 3736391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
    Sun Y; Liou B; Quinn B; Ran H; Xu YH; Grabowski GA
    PLoS One; 2009 Oct; 4(10):e7320. PubMed ID: 19809509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation).
    Zimmer KP; le Coutre P; Aerts HM; Harzer K; Fukuda M; O'Brien JS; Naim HY
    J Pathol; 1999 Aug; 188(4):407-14. PubMed ID: 10440752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry.
    Willemsen R; van Dongen JM; Ginns EI; Sips HJ; Schram AW; Tager JM; Barranger JA; Reuser AJ
    J Neurol; 1987 Jan; 234(1):44-51. PubMed ID: 3819786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease.
    Tsuji S; Choudary PV; Martin BM; Stubblefield BK; Mayor JA; Barranger JA; Ginns EI
    N Engl J Med; 1987 Mar; 316(10):570-5. PubMed ID: 2880291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease.
    Farfel-Becker T; Vitner E; Dekel H; Leshem N; Enquist IB; Karlsson S; Futerman AH
    Hum Mol Genet; 2009 Apr; 18(8):1482-8. PubMed ID: 19193629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.
    Tybulewicz VL; Tremblay ML; LaMarca ME; Willemsen R; Stubblefield BK; Winfield S; Zablocka B; Sidransky E; Martin BM; Huang SP
    Nature; 1992 Jun; 357(6377):407-10. PubMed ID: 1594045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infantile Gaucher's disease: glucocerebrosidase deficiency in peripheral blood leukocytes and cultured fibroblasts.
    Sengers RC; Lamers KJ; Bakkeren JA; Schretlen ED; Trijbels JM
    Neuropadiatrie; 1975 Nov; 6(4):377-82. PubMed ID: 241947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of fluorescent substrates for characterization of Gaucher disease mutations.
    Ron I; Dagan A; Gatt S; Pasmanik-Chor M; Horowitz M
    Blood Cells Mol Dis; 2005; 35(1):57-65. PubMed ID: 15916907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preclinical research of a new therapy for Gaucher's disease with F213I mutation].
    Hou L; Kousaku O
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Oct; 20(5):381-4. PubMed ID: 14556188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.